Retinal pressure autoregulation is an important mechanism that protects the retina by stabilizing retinal blood flow during changes in arterial or intraocular pressure. Similar to other vascular beds, retinal pressure autoregulation is thought to be mediated largely through the myogenic response of small arteries and arterioles which constrict when transmural pressure increases or dilate when it decreases.
Over recent years, we and others have investigated the signaling pathways underlying the myogenic response in retinal arterioles, with particular emphasis on the involvement of different ion channels expressed in the smooth muscle layer of these vessels.
Here, we review and extend previous work on the expression and spatial distribution of the plasma membrane and sarcoplasmic reticulum ion channels present in retinal vascular smooth muscle cells (VSMCs) and discuss their contribution to pressure-induced myogenic tone in retinal arterioles.
This includes new data demonstrating that several key players and modulators of the myogenic response show distinctively heterogeneous expression along the length of the retinal arteriolar network, suggesting differences in myogenic signaling between larger and smaller pre-capillary arterioles.
4-Arm PEG-MA |
abx085177-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 610.8 |
|
4-Arm PEG-MA |
abx085177-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 610.8 |
|
4-Arm PEG-MA |
abx085177-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 1228.8 |
|
4-Arm PEG-MA |
abx085177-5kDa1g |
Abbexa |
5 kDa; 1 g |
EUR 577.2 |
|
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
Cy3.5-PEG-Mal |
abx085322-10kDa500mg |
Abbexa |
10 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-5kDa500mg |
Abbexa |
5 kDa; 500 mg |
EUR 961.2 |
|
PCL(12K)-PEG-Mal |
abx085326-10kDa500mg |
Abbexa |
10 kDa; 500 mg |
EUR 1144.8 |
|
PCL(12K)-PEG-Mal |
abx085326-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 1144.8 |
|
PCL(12K)-PEG-Mal |
abx085326-5kDa500mg |
Abbexa |
5 kDa; 500 mg |
EUR 1144.8 |
|
PLGA(5K)-PEG-Mal |
abx085332-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 1245.6 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-05kDa500mg |
Abbexa |
0.5 kDa; 500 mg |
EUR 1296 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-1kDa500mg |
Abbexa |
1 kDa; 500 mg |
EUR 1446 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 1479.6 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 1479.6 |
|
4-Arm PEG-Mal |
abx085089-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 477.6 |
|
4-Arm PEG-Mal |
abx085089-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 477.6 |
|
4-Arm PEG-Mal |
abx085089-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 844.8 |
|
4-Arm PEG-Mal |
abx085089-5kDa1g |
Abbexa |
5 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 961.2 |
|
8-Arm PEG-Mal |
abx085119-40kDa1g |
Abbexa |
40 kDa; 1 g |
EUR 444 |
|
PCL(12K)-PEG-Mal,2K |
HE062022-2K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(12K)-PEG-Mal,5K |
HE062022-5K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,2K |
HE085022-2K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,3.4K |
HE085022-3.4K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,5K |
HE085022-5K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,1K |
HE086022-1K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,2K |
HE086022-2K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,3.4K |
HE086022-3.4K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,500 |
HE086022-500-500mg |
Biochempeg |
500mg |
EUR 918 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,5K |
HE086022-5K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,2K |
FL077022-2K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,3.4K |
FL077022-3.4K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,5K |
FL077022-5K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
4-Arm PEG-Mal |
abx085089-100l |
Abbexa |
100 µl |
EUR 300 |
4-Arm PEG-Mal |
abx085089-1ml |
Abbexa |
1 ml |
EUR 312.5 |
4-Arm PEG-Mal |
abx085089-200l |
Abbexa |
200 µl |
EUR 312.5 |
8-Arm PEG-Mal |
abx085119-100l |
Abbexa |
100 µl |
EUR 300 |
8-Arm PEG-Mal |
abx085119-1ml |
Abbexa |
1 ml |
EUR 300 |
8-Arm PEG-Mal |
abx085119-200l |
Abbexa |
200 µl |
EUR 300 |
Cy3.5-PEG-Mal |
abx085322-100l |
Abbexa |
100 µl |
EUR 662.5 |
Cy3.5-PEG-Mal |
abx085322-1ml |
Abbexa |
1 ml |
EUR 662.5 |
Cy3.5-PEG-Mal |
abx085322-200l |
Abbexa |
200 µl |
EUR 662.5 |
PCL(12K)-PEG-Mal,10K |
HE062022-10K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(12K)-PEG-Mal,20K |
HE062022-20K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,2K |
33-HE088022-2K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,3.4K |
33-HE088022-3.4K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,5K |
33-HE088022-5K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(18K)-PEG-MAL,3.4K |
33-HE118022-3.4K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,10K |
FL077022-10K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,20K |
FL077022-20K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(30K)-PEG-Mal |
abx085340-100l |
Abbexa |
100 µl |
EUR 625 |
PLGA(30K)-PEG-Mal |
abx085340-1ml |
Abbexa |
1 ml |
Ask for price |
PLGA(30K)-PEG-Mal |
abx085340-200l |
Abbexa |
200 µl |
EUR 1025 |
PEG3-methylamine |
T16457-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: PEG3-methylamine |
Anti-TACSTD2 (clone 7E6)-PEG6-MMAD ADC |
ADC-W-292 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone 7E6) conjugated via a PEG6 linker to MMAD |
Anti-TACSTD2 (clone C16)-PEG6-MMAD ADC |
ADC-W-538 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone C16) conjugated via a PEG6 linker to MMAD |
4-Arm PEG-Methacrylate |
abx085177-100l |
Abbexa |
100 µl |
EUR 362.5 |
4-Arm PEG-Methacrylate |
abx085177-1ml |
Abbexa |
1 ml |
EUR 362.5 |
4-Arm PEG-Methacrylate |
abx085177-200l |
Abbexa |
200 µl |
EUR 362.5 |
Anti-MUC1 (clone huC242)-PEG4Mal-DM1 ADC |
ADC-W-313 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-MUC1 monoclonal antibody (clone huC242) conjugated via a PEG4Mal linker to a DM1 |
Anti-TNFRSF17 (clone 2A1)-PEG4-Mal-DM4 ADC |
ADC-W-121 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TNFRSF17 monoclonal antibody (clone 2A1) conjugated via a PEG4-Mal linker to DM4 |
Anti-TNFRSF17 (clone 1E1)-PEG4-Mal-DM4 ADC |
ADC-W-125 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TNFRSF17 monoclonal antibody (clone 1E1) conjugated via a PEG4-Mal linker to DM4 |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
Polyethylene glycol monomethacrylate (PEGMA 200) |
16712-100 |
Polysciences Europe GmbH |
100g |
EUR 332 |
Description: 25736-86-1 |
Polyethylene glycol monomethacrylate (PEGMA 400) |
16713-100 |
Polysciences Europe GmbH |
100g |
EUR 111 |
Description: 25736-86-1 |
Polyethylene glycol monomethacrylate (PEGMA 440) |
24890-1000 |
Polysciences Europe GmbH |
1kg |
EUR 420 |
Description: 25736-86-1 |
AzoDye-1 PEG10 Alkyne |
2415-1mg |
AAT Bioquest |
1 mg |
EUR 151 |
|
Description: AzoDye-1 PEG10 alkyne is an excellent building block for labeling azide-containing molecules. |
PEG3-tetrazine, 1 g |
1978-1g |
Lumiprobe |
1 g |
EUR 793.2 |
AzoDye-1 PEG10 Succinimidyl Ester |
2403-5mg |
AAT Bioquest |
5 mg |
EUR 97 |
|
Description: AzoDye-1 PEG10 Succinimidyl Ester is an excellent building block for labeling amino-containing molecules. |
JBScreen Membrane 1 (PEG 400 to PEG 2000 MME based) |
M-CS-301L |
MiTeGen |
24 solutions |
EUR 414 |
Description: JBScreen Membrane 1 (PEG 400 to PEG 2000 MME based) |
PEG3 dicarboxylic acid, 1 g |
1715-1g |
Lumiprobe |
1 g |
EUR 423.6 |
JBScreen Classic 1 (PEG 400 to 3000 based) |
M-CS-101L |
MiTeGen |
24 solutions |
EUR 249 |
Description: JBScreen Classic 1 (PEG 400 to 3000 based) |
Lenti ORF clone of Peg10 (mGFP-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 1 |
MR224445L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg12 sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6370802 |
ABM |
1.0 ug DNA |
EUR 184.8 |
PEG30K-Cys-AEEAc-Fibrinopeptide A (1-15) |
4066201.05 |
Bachem |
0.5 mg |
EUR 240.45 |
|
PEG30K-Cys-AEEAc-Fibrinopeptide A (1-15) |
4066201.1 |
Bachem |
1 mg |
EUR 422.42 |
|
PEG30K-Cys-AEEAc-Fibrinopeptide A (1-15) |
H-8348.0500 |
Bachem |
0.5mg |
EUR 410.4 |
Description: Sum Formula: C66H101N17O29S+PEG30K |
PEG30K-Cys-AEEAc-Fibrinopeptide A (1-15) |
H-8348.1000 |
Bachem |
1.0mg |
EUR 691.2 |
Description: Sum Formula: C66H101N17O29S+PEG30K |
PEG10 sgRNA CRISPR Lentivector (Human) (Target 1) |
K1626702 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg12 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3769502 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg10 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4676402 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Biotin PEG2 amine *CAS 138529-46-1* |
3014-5mg |
AAT Bioquest |
5 mg |
EUR 109 |
|
Description: This carbonyl-reactive biotin derivative contains a long arm (~20 angstrom) increase its avidin-binding affinity. |
PEG10 (untagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
SC318188 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (untagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
SC108513 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (untagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
SC324334 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (untagged)-Human paternally expressed 10 (PEG10) transcript variant 1 |
SC328573 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Peg10 (Myc-DDK-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 1 |
MR224445L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg10 (untagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, (10ug) |
MC223182 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1 |
RG231501 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1 |
RG223371 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1 |
RG229935 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1 |
RG208683 |
Origene Technologies GmbH |
10 µg |
Ask for price |
JBScreen PEG/Salt 1 |
M-CS-141 |
MiTeGen |
24 solutions |
EUR 263 |
Description: JBScreen PEG/Salt 1 |
Lenti ORF particles, Peg10 (GFP-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 1, 200ul, >10^7 TU/mL |
MR224445L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Peg10 (Myc-DDK-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1 |
MR224445 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg10 (Myc-DDK-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1 |
MR225144 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg10 (GFP-tagged) - Mouse paternally expressed 10 (Peg10) transcript variant 1, (10ug) |
MG224445 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg10 (GFP-tagged) - Mouse paternally expressed 10 (Peg10) transcript variant 1, (10ug) |
MG225144 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC208683 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC223371 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC231501 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC229935 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, Peg10 (Myc-DDK-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 1, 200ul, >10^7 TU/mL |
MR224445L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
PEG3 (untagged)-Human paternally expressed 3 (PEG3), transcript variant 1 |
SC128281 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 sgRNA CRISPR Lentivector (Human) (Target 1) |
K1626502 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg3 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4341802 |
ABM |
1.0 ug DNA |
EUR 184.8 |
PEG3AS sgRNA CRISPR Lentivector (Human) (Target 1) |
K1626602 |
ABM |
1.0 ug DNA |
EUR 184.8 |
iFluor®488-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17041 |
AAT Bioquest |
25 nmoles |
EUR 101 |
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labelled DNA via the conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
iFluor®488-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17041-25nmoles |
AAT Bioquest |
25 nmoles |
EUR 99 |
|
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labelled DNA via the conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
iFluor®555-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17042 |
AAT Bioquest |
25 nmoles |
EUR 101 |
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labelled DNA via the conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
iFluor®555-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17042-25nmoles |
AAT Bioquest |
25 nmoles |
EUR 99 |
|
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labelled DNA via the conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
iFluor®647-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17043 |
AAT Bioquest |
25 nmoles |
EUR 101 |
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labeled DNA via conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
iFluor®647-PEG12-dUTP *1 mM in Tris Buffer (pH 7.5)* |
17043-25nmoles |
AAT Bioquest |
25 nmoles |
EUR 99 |
|
Description: The dye-modified deoxyuridine 5'-triphosphates are one of the most common methods to produce dye-labelled DNA via the conventional enzymatic incorporation methods such as reverse transcription, nick translation, random primed labeling, or PCR. |
JBScreen PEG/Salt 1 - 4 |
M-CS-145 |
MiTeGen |
4 Kits |
EUR 858 |
Description: JBScreen PEG/Salt 1 - 4 |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 1 |
RG215328 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (Myc-DDK-tagged)-Human paternally expressed 3 (PEG3), transcript variant 1 |
RC215328 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Peg12 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
K6370806 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Lenti-ORF clone of PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC223371L2 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti-ORF clone of PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC223371L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti-ORF clone of PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC231501L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG10 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
K1626706 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Peg12 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3769506 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Peg10 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K4676406 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Lenti-ORF clone of PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC223371L1 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti-ORF clone of PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC223371L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti-ORF clone of PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1 |
RC231501L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Peg10 (mGFP-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 2 |
MR225144L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC208683L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC223371L2V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC223371L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC231501L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC229935L2V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (mGFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC229935L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC208683L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC229935L1V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK tagged) - Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC229935L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF clone of Peg10 (Myc-DDK-tagged) - Mouse paternally expressed 10 (Peg10), transcript variant 1, encoding isoform 2 |
MR225144L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC223371L1V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC223371L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 1, 200ul, >10^7 TU/mL |
RC231501L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
PEG3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
K1626506 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Peg3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K4341806 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Our immunohistochemical investigations have also highlighted the presence of actin-containing microstructures called myobridges that connect the retinal VSMCs to one another. Although further work is still needed, studies to date investigating myogenic mechanisms in the retina have contributed to a better understanding of how blood flow is regulated in this tissue. They also provide a basis to direct future research into retinal diseases where blood flow changes contribute to the pathology.